{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:24:00Z","timestamp":1782879840348,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00261-015-0560-3","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T12:15:58Z","timestamp":1450786558000},"page":"207-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis"],"prefix":"10.1007","volume":"41","author":[{"given":"Andrew R.","family":"Barina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa R.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Hanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"560_CR1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","volume":"18","author":"KS Peggs","year":"2006","unstructured":"Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206\u2013213","journal-title":"Curr Opin Immunol"},{"key":"560_CR2","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"L Fong","year":"2008","unstructured":"Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275\u20135283","journal-title":"J Clin Oncol"},{"key":"560_CR3","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","volume":"110","author":"SJ O\u2019Day","year":"2007","unstructured":"O\u2019Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Cancer 110:2614\u20132627","journal-title":"Cancer"},{"key":"560_CR4","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","volume":"14","author":"C Robert","year":"2009","unstructured":"Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14:848\u2013861","journal-title":"Oncologist"},{"key":"560_CR5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","volume":"58","author":"J Weber","year":"2009","unstructured":"Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823\u2013830","journal-title":"Cancer Immunol Immunother"},{"key":"560_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"560_CR7","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"S O\u2019day","year":"2010","unstructured":"O\u2019day S, Maio M, Chiarion-Sileni V, et al. (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21:1712\u20131717","journal-title":"Ann Oncol"},{"key":"560_CR8","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, et al. (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591\u20135598","journal-title":"Clin Cancer Res"},{"key":"560_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, et al. (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155\u2013164","journal-title":"Lancet Oncol"},{"key":"560_CR10","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691\u20132697","journal-title":"J Clin Oncol"},{"key":"560_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","volume":"37","author":"AM Giacomo Di","year":"2010","unstructured":"Di Giacomo AM, Biagioli M, Maio M (2010) The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 37:499\u2013507","journal-title":"Semin Oncol"},{"issue":"1","key":"560_CR12","first-page":"11","volume":"10","author":"D Berman","year":"2010","unstructured":"Berman D, Parker SM, Siegel J, et al. (2010) Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10(1):11","journal-title":"Cancer Immun"},{"key":"560_CR13","doi-asserted-by":"crossref","first-page":"W241","DOI":"10.2214\/AJR.10.6032","volume":"197","author":"KN O\u2019Regan","year":"2011","unstructured":"O\u2019Regan KN, Jagannathan JP, Ramaiya N, Hodi FS (2011) Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. Am J Roentgenol 197:W241\u2013W246","journal-title":"Am J Roentgenol"},{"key":"560_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","volume":"37","author":"A Lyall","year":"2012","unstructured":"Lyall A, Vargas HA, Carvajal RD, Ulaner G (2012) Ipilimumab-induced colitis on FDG PET\/CT. Clin Nucl Med 37:629\u2013630","journal-title":"Clin Nucl Med"},{"key":"560_CR15","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu W-J (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am J Roentgenol 197:W992\u2013W1000","journal-title":"Am J Roentgenol"},{"key":"560_CR16","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","volume":"200","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, et al. (2013) Ipilimumab-associated colitis: CT findings. Am J Roentgenol 200:W468\u2013W474","journal-title":"Am J Roentgenol"},{"key":"560_CR17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.2403050818","volume":"240","author":"RF Thoeni","year":"2006","unstructured":"Thoeni RF, Cello JP (2006) CT imaging of colitis 1. Radiology 240:623\u2013638","journal-title":"Radiology"},{"key":"560_CR18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2214\/ajr.176.5.1761105","volume":"176","author":"M Macari","year":"2001","unstructured":"Macari M, Balthazar EJ (2001) CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol 176:1105\u20131116","journal-title":"AJR Am J Roentgenol"},{"key":"560_CR19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1572-0241.2002.05691.x","volume":"97","author":"G Latella","year":"2002","unstructured":"Latella G, Vernia P, Viscido A, et al. (2002) GI distension in severe ulcerative colitis. Am J Gastroenterol 97:1169\u20131175","journal-title":"Am J Gastroenterol"},{"key":"560_CR20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1148\/radiol.2263011932","volume":"226","author":"ID Kirkpatrick","year":"2003","unstructured":"Kirkpatrick ID, Greenberg HM (2003) Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT 1. Radiology 226:668\u2013674","journal-title":"Radiology"},{"key":"560_CR21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0b013e318217399e","volume":"36","author":"B Bybel","year":"2011","unstructured":"Bybel B, Greenberg ID, Paterson J, Ducharme J, Leslie WD (2011) Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case\u2013control analysis. Clin Nucl Med 36:452\u2013456","journal-title":"Clin Nucl Med"},{"key":"560_CR22","unstructured":"Health NIo (2010) Common terminology criteria for adverse events (CTCAE), version 4.0. In. Bethesda, MD: U.S. Department of Health and Human Services"},{"key":"560_CR23","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ, et al. (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283\u20132289","journal-title":"J Clin Oncol"},{"issue":"5","key":"560_CR24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","volume":"37","author":"KC Kaehler","year":"2010","unstructured":"Kaehler KC, Piel S, Livingstone E, et al. (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37(5):485\u2013498","journal-title":"Semin Oncol"},{"key":"560_CR25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3748\/wjg.v18.i16.1871","volume":"18","author":"HJ Freeman","year":"2012","unstructured":"Freeman HJ (2012) Colitis associated with biological agents. World J Gastroenterol 18:1871","journal-title":"World J Gastroenterol"},{"key":"560_CR26","first-page":"11","volume":"10","author":"D Berman","year":"2010","unstructured":"Berman D, Parker SM, Siegel J, et al. (2010) Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun Arch 10:11","journal-title":"Cancer Immun Arch"},{"key":"560_CR27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer 119:1675\u20131682","journal-title":"Cancer"},{"key":"560_CR28","first-page":"857519","volume":"2013","author":"A Tarhini","year":"2014","unstructured":"Tarhini A (2014) Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013:857519","journal-title":"Scientifica"},{"key":"560_CR29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","volume":"30","author":"JC Yang","year":"2007","unstructured":"Yang JC, Hughes M, Kammula U, et al. (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (Hagerstown, Md: 1997) 30:825","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"560_CR30","first-page":"94","volume":"86","author":"P Dilling","year":"2014","unstructured":"Dilling P, Walczak J, Pikiel P, Kruszewski WJ (2014) Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab\u2014case report. Pol J Surg 86:94\u201396","journal-title":"Pol J Surg"},{"key":"560_CR31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","volume":"47","author":"KA Mitchell","year":"2013","unstructured":"Mitchell KA, Kluger H, Sznol M, Hartman DJ (2013) Ipilimumab-induced perforating colitis. J Clin Gastroenterol 47:781\u2013785","journal-title":"J Clin Gastroenterol"},{"key":"560_CR32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/cbr.2008.0607","volume":"24","author":"DR Minor","year":"2009","unstructured":"Minor DR, Chin K, Kashani-Sabet M (2009) Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 24:321\u2013325","journal-title":"Cancer Biother Radiopharm"},{"key":"560_CR33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","volume":"18","author":"LA Fecher","year":"2013","unstructured":"Fecher LA, Agarwala SS, Hodi FS, Weber JS (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18:733\u2013743","journal-title":"Oncologist"},{"key":"560_CR34","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1245\/s10434-014-4268-3","volume":"22","author":"N Wasif","year":"2015","unstructured":"Wasif N, Etzioni D, Haddad D, et al. (2015) Staging studies for cutaneous melanoma in the United States: a population-based analysis. Ann Surg Oncol 22:1366\u20131370","journal-title":"Ann Surg Oncol"},{"key":"560_CR35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00259-010-1702-z","volume":"38","author":"T Pfluger","year":"2011","unstructured":"Pfluger T, Melzer HI, Schneider V, et al. (2011) PET\/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging 38:822\u2013831","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"560_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2006.10.024","volume":"5","author":"LW Lamps","year":"2007","unstructured":"Lamps LW, Knapple WL (2007) Diverticular disease-associated segmental colitis. Clin Gastroenterol Hepatol 5:27\u201331","journal-title":"Clin Gastroenterol Hepatol"},{"key":"560_CR37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00384-004-0615-3","volume":"20","author":"I Koutroubakis","year":"2005","unstructured":"Koutroubakis I, Antoniou P, Tzardi M, Kouroumalis E (2005) The spectrum of segmental colitis associated with diverticulosis. Int J Colorectal Dis 20:28\u201332","journal-title":"Int J Colorectal Dis"},{"key":"560_CR38","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/j.1572-0241.2008.01879.x","volume":"103","author":"AA Sheth","year":"2008","unstructured":"Sheth AA, Longo W, Floch MH (2008) Diverticular disease and diverticulitis. Am J Gastroenterol 103:1550\u20131556","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"560_CR39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"key":"560_CR40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"},{"issue":"8","key":"560_CR41","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918","journal-title":"Lancet Oncol"},{"key":"560_CR42","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"560_CR43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133","journal-title":"N Engl J Med"},{"issue":"5","key":"560_CR44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.seminoncol.2010.09.006","volume":"37","author":"L Calabr\u00f2","year":"2010","unstructured":"Calabr\u00f2 L, Danielli R, Sigalotti L, Maio M (2010) Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 37(5):460\u2013467","journal-title":"Semin Oncol"},{"key":"560_CR45","first-page":"929","volume":"8","author":"TC Gangadhar","year":"2015","unstructured":"Gangadhar TC, Salama AK (2015) Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets Therapy 8:929","journal-title":"OncoTargets Therapy"},{"key":"560_CR46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/onci.1.1.17938","volume":"1","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Vacchelli E, Fridman WH, et al. (2012) Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 1:28\u201337","journal-title":"Oncoimmunology"},{"key":"560_CR47","first-page":"187","volume":"1836","author":"S Mocellin","year":"2013","unstructured":"Mocellin S, Nitti D (2013) CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochimica et Biophysica 1836:187\u2013196","journal-title":"Biochimica et Biophysica"},{"key":"560_CR48","first-page":"3049","volume":"27","author":"E Wang","year":"2009","unstructured":"Wang E, Kang D, Wang D, Bulanhagui C, Hsyu P (2009) Relationship between pharmacokinetics and safety of tremelimumab in patients with melanoma. ASCO Ann Meeting Proc 27:3049","journal-title":"ASCO Ann Meeting Proc"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-015-0560-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00261-015-0560-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-015-0560-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T03:40:33Z","timestamp":1599968433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00261-015-0560-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1007\/s00261-015-0560-3","relation":{},"ISSN":["2366-004X","2366-0058"],"issn-type":[{"value":"2366-004X","type":"print"},{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}